Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Ho

Showing results (71-80 of 241) with videos related to

Pageof 25
Sort By:
Iscience|November 8, 2021
Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concernQian Wang, Manoj S Nair, Saumya Anang, et al.
Cell Reports|June 6, 2022
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529Qian Wang, Saumya Anang, Sho Iketani, et al.
The Lancet. Infectious Diseases|April 1, 2023
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent boosterQian Wang, Anthony Bowen, Anthony R Tam, et al.
Emerging Microbes & Infections|February 4, 2016
Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliCChandrabali Ghose, Ioannis Eugenis, Xingmin Sun, et al.
Emerging Microbes & Infections|November 15, 2021
Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccinationSho Iketani, Lihong Liu, Manoj S Nair, et al.
Journal of Virology|September 16, 2004
Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infectionMichele Di Mascio, Martin Markowitz, Michael Louie, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 30, 2016
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific AntibodiesRuijiang Song, Craig Pace, Michael S Seaman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 24, 2014
Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36Ming Sun, Craig S Pace, Xin Yao, et al.
European Journal of Immunology|December 14, 2004
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virusSarah Tuttleton Arron, Ruy M Ribeiro, Agegnehu Gettie, et al.
Molecular Therapy. Methods & Clinical Development|October 17, 2017
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola InfectionsChasity D Andrews, Yang Luo, Ming Sun, et al.
Pageof 25

Showing results (71-80 of 241) with videos related to

Sort By:
Pageof 25
Iscience|November 8, 2021
Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concernQian Wang, Manoj S Nair, Saumya Anang, et al.
Cell Reports|June 6, 2022
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529Qian Wang, Saumya Anang, Sho Iketani, et al.
The Lancet. Infectious Diseases|April 1, 2023
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent boosterQian Wang, Anthony Bowen, Anthony R Tam, et al.
Emerging Microbes & Infections|February 4, 2016
Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliCChandrabali Ghose, Ioannis Eugenis, Xingmin Sun, et al.
Emerging Microbes & Infections|November 15, 2021
Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccinationSho Iketani, Lihong Liu, Manoj S Nair, et al.
Journal of Virology|September 16, 2004
Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infectionMichele Di Mascio, Martin Markowitz, Michael Louie, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 30, 2016
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific AntibodiesRuijiang Song, Craig Pace, Michael S Seaman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 24, 2014
Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36Ming Sun, Craig S Pace, Xin Yao, et al.
European Journal of Immunology|December 14, 2004
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virusSarah Tuttleton Arron, Ruy M Ribeiro, Agegnehu Gettie, et al.
Molecular Therapy. Methods & Clinical Development|October 17, 2017
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola InfectionsChasity D Andrews, Yang Luo, Ming Sun, et al.
Pageof 25